Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | VDR | P11473 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26353810 | 0.97 | CES2 (0.42) | CES2MAPK1ALDH1A1HTTVDR | |
| SCHEMBL25725933 | 0.97 | CES2 (0.42) | CES2MAPK1ALDH1A1HTTVDR | |
| SCHEMBL6840501 | 0.91 | CES2 (0.38) | CES2MAPK1ALDH1A1HTTVDR | |
| SCHEMBL10001210 | 0.91 | CES2 (0.38) | CES2MAPK1ALDH1A1HTTVDR | |
| SCHEMBL17208236 | 0.91 | ALDH1A1 (0.46) | CES2MAPK1ALDH1A1HTTVDR | |
| SCHEMBL17516305 | 0.89 | CES2 (0.37) | CES2MAPK1ALDH1A1HTTVDR | |
| SCHEMBL6840509 | 0.89 | CES2 (0.37) | CES2MAPK1ALDH1A1HTTVDR | |
| SCHEMBL12592823 | 0.89 | CES2 (0.37) | CES2MAPK1ALDH1A1HTTVDR | |
| SCHEMBL18651066 | 0.89 | MEN1 (0.48) | CES2MAPK1ALDH1A1HTTVDR | |
| SCHEMBL17913990 | 0.89 | CES2 (0.46) | CES2MAPK1ALDH1A1HTTVDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20230295610-A1 | DNA-ENCODED COMPOUND LIBRARY AND SCREENING METHOD THEREOF | HITGEN INC (CN) | 2023-09-21 | — | — | US | disclosed |
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | GLYCOMIMETICS, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | GLYCOMIMETICS, INC. (US) | 2023-05-11 | — | — | US | disclosed |
| US-10017556-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165882-A1 | COMPOUNDS AND METHODS FOR REDUCTION OF CANCER CELL BURDEN AND PROTECTION OF NORMAL HEMATOPOIESIS | FLT3, SELE, SELL | CES2 2168/4885MAPK1 2131/4885ALDH1A1 1066/4885 |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | CES2 2734/4885MAPK1 3170/4885ALDH1A1 4716/4885 |
| US-20230147312-A1 | TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME AND RELATED CONDITIONS WITH ANTAGONISTS OF E-SELECTIN | SELP, SELE, SELPLG | CES2 1781/4885MAPK1 3462/4885ALDH1A1 1201/4885 |
| US-10017556-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | CES2 2734/4885MAPK1 3170/4885ALDH1A1 4716/4885 |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | CES2 2734/4885MAPK1 3170/4885ALDH1A1 4716/4885 |
| US-20230310551-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | CES2 2734/4885MAPK1 3170/4885ALDH1A1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.